Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
Status:
Completed
Trial end date:
2010-04-22
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety of LDX administered
as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years
of age inclusive at the time of consent).